Suggestions
Ingrid Teigland Akay, MD MBA
Managing Partner at Hadean Ventures
Ingrid Teigland Akay, MD, MBA, is a prominent figure in the healthcare and biotechnology sectors. She currently serves as a board member at Alex Therapeutics, a company specializing in digital therapeutics, where she plays a crucial role in guiding its strategic direction and growth initiatives.12
Professional Background
Dr. Akay is the founder and managing partner at Hadean Ventures, a venture capital firm that invests in early-stage life sciences companies. Her expertise spans various areas including research and development, commercialization, and clinical practice. She has experience in general medicine, surgery, and psychiatry, which equips her with a comprehensive understanding of both healthcare delivery and business operations.12
Education
Dr. Akay holds a medical degree from Medizinische Hochschule Hannover and an MBA in Finance from London Business School. This combination of medical training and business acumen enables her to navigate the complexities of the healthcare industry effectively.14
Contributions
In her role at Alex Therapeutics, Dr. Akay has been involved in significant financing efforts aimed at expanding the company's capabilities in developing prescription digital therapies. Her leadership is instrumental in fostering partnerships with pharmaceutical companies to enhance patient outcomes through innovative therapeutic solutions.23
Dr. Akay's extensive background and strategic insights make her a valuable asset to both Alex Therapeutics and the broader life sciences community.
Highlights
#Ovariancancer is a Women's Health issue with high unmet medical need and remains a leading cause of death from gynecology malignancy . About 75% of patients already have peritoneal metastasis at diagnosis and these metastases have a particularly negative impact on life expectancy.
An effective treatment therefore has a significant chance of affecting overall survival in these patients. Hadean Ventures portfolio company Oncoinvent ASA today announced that it has received #FDA Fast Track Designation for its lead product Radspherin in this indication - next up phase 2b! #radiopharma #hadeanventures #oncoinvent
https://lnkd.in/dTA2TBdY
Pleased to welcome the new board of Hadean Ventures' portfolio company Oncoinvent AS! Gillies O'Bryan-Tear, Orlando Oliveira, Hilde H. Steineger, Kari Grønås (prev. Dyvik), Markus Dietrich, PhD. Looking forward to a great collaboration!
#hadeanventures #oncoinvent #radiopharmaceuticals
